预约演示
更新于：2025-04-17
Loxoprofen Sodium Hydrate
洛索洛芬钠
更新于：2025-04-17
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H20NaO4 |
InChIKeyNGHFIMBWFYJBHQ-UHFFFAOYSA-N |
CAS号226721-96-6 |
关联
112
项与 洛索洛芬钠 相关的临床试验ChiCTR2500097025
Postoperative application of loxoprofen sodium tablets for the prevention of post-implantation syndrome after thoracic endovascular aortic repair: A single-center, prospective, randomized controlled study
CTR20250916
洛索洛芬钠贴剂人体生物等效性研究
CTR20250487
洛索洛芬钠贴剂人体生物等效性研究
100 项与 洛索洛芬钠 相关的临床结果
登录后查看更多信息
100 项与 洛索洛芬钠 相关的转化医学
登录后查看更多信息
100 项与 洛索洛芬钠 相关的专利（医药）
登录后查看更多信息
1,262
项与 洛索洛芬钠 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study
Article
作者: Zhang, Jinying ; Liu, Naifeng ; Fang, Lijuan ; Wang, Zhenwei ; Shi, Qian ; Tang, Junnan
AIMS:
To assess the link between persistent lipoprotein(a) [Lp(a)] exposure levels and clinical outcomes in patients with acute myocardial infarction (AMI).
METHODS:
This longitudinal cohort study included 1131 AMI patients, categorizing persistent Lp(a) exposure based on measurements at admission and after 1 year. Patients were segmented into four groups using a 300 mg/L Lp(a) threshold: (1) persistent low Lp(a) (lowon admission - lowat 1 year); (2) fortified Lp(a) (lowon admission - highat 1 year); (3) attenuated Lp(a) (highon admission - lowat 1 year); and (4) persistent high Lp(a) (highon admission - highat 1 year). Multivariate Cox regression, subgroup analysis and sensitivity analysis assessed the association between Lp(a) trajectories and major adverse cardiovascular and cerebrovascular events (MACCE), cardiovascular death, non-fatal MI, non-fatal stroke, unplanned revascularization, and all-cause death.
RESULTS:
Over a median 50-month follow-up, 343 (35.70%) patients encountered MACCE, and 210 (18.70%) died, including 126 (11.20%) from cardiovascular causes. The group with persistent high Lp(a) faced increased risk of MACCE (HRadjusted, 1.871; 95% CI: 1.474-2.374), non-fatal stroke (HRadjusted, 1.647; 95% CI: 1.031-2.632), unplanned revascularization (HRadjusted, 1.571; 95% CI: 1.008-2.449), and both all-cause (HRadjusted, 1.546; 95% CI: 1.134-2.108) and cardiovascular death (HRadjusted, 2.163; 95% CI: 1.405-3.331), compared to the persistent low Lp(a) group.
CONCLUSIONS:
In AMI patients, sustained high Lp(a) levels were significantly associated with increased risk of MACCE, non-fatal stroke, unplanned revascularization, and both all-cause and cardiovascular death.
2025-12-01Journal of Sport and Health Science
Accelerometer-measured physical activity, sedentary behavior, and incidence of macrovascular and microvascular events in individuals with type 2 diabetes mellitus and prediabetes
Article
作者: Du, Jing ; He, Yu ; Liu, Yaping ; Xue, Huachen ; Ai, Sizhi ; Zhang, Jihui ; Zhang, Jun ; Li, Haiteng ; Qi, Lu ; Liang, Yannis Yan ; Feng, Hongliang ; Huang, Piao
BACKGROUND:
Physical activity (PA) is considered beneficial for lowering cardiovascular risks following type 2 diabetes mellitus (T2DM) and prediabetes, but existing evidence relies mainly on self-reported measurements. We aimed to describe the intensity-specific dose-response associations of PA and sedentary behavior (SB) with macrovascular and microvascular events among individuals with T2DM and prediabetes.
METHODS:
This study included 11,474 individuals with T2DM and prediabetes from the UK Biobank. PA, including total PA, moderate-to-vigorous intensity PA (MVPA), light-intensity PA (LPA), and SB, were measured by accelerometers over 7 days. MVPA was categorized according to the American Diabetes Association guideline-recommended level (at least 150 min/week), and total PA, LPA, and SB were grouped by tertiles. The outcomes were incidences of macrovascular events, microvascular events, heart failure (HF), and their combination (composite events). The events were ascertained using the International Classification of Diseases-10 (ICD-10) codes on the hospital or death records.
RESULTS:
During a median follow-up of 6.8 years, 1680 cases were documented, including 969 macrovascular events, 839 microvascular events, and 284 incidents of HF. Accelerometer-measured PA, irrespective of intensity, was inversely associated with the risk of composite events and each outcome in the dose-response patterns. Regarding categorized PA, engagement in total PA (high vs. low) was associated with decreased risk of macrovascular events (hazard ratio (HR) = 0.80; 95% confidence interval (95%CI): 0.67-0.95), microvascular events (HR = 0.76; 95%CI: 0.63-0.93), and HF (HR = 0.46; 95%CI: 0.32-0.66). Adherence to MVPA, but not LPA, above the guideline-recommended level (at least 150 min/week) was associated with reduced risk of macrovascular events (HR = 0.80; 95%CI: 0.68-0.95), microvascular events (HR = 0.76; 95%CI: 0.63-0.92), and HF (HR = 0.65; 95%CI: 0.46-0.92). The minimum dose of MVPA for lowering the risk of composite events was approximately 59.0 min/week. More time spent in SB was associated with an increased risk of composite events (high vs. low, HR = 1.17; 95%CI: 1.02-1.35) and HF (high vs. low, HR = 1.54; 95%CI: 1.09-2.20). Replacement of 30 min of SB (HR = 0.73; 95%CI: 0.65-0.81) and LPA (HR = 0.74; 95%CI: 0.66-0.83) with MVPA dramatically reduced the risk of composite events.
CONCLUSION:
Adherence to a higher amount of accelerometer-measured PA, especially MVPA at least 59 min/week, is associated with reduced risks of macrovascular and microvascular events among individuals with T2DM and prediabetes. Replacement of SB and LPA with MVPA helped lower the risk of diabetic vascular events.
2025-04-01ADVANCED SYNTHESIS & CATALYSIS
Iron Catalyzed Radical Alkylation of Cyclic Ketimines with Olefins via Metal Hydride Atom Transfer
作者: Sun, Ruizhi ; Hu, Xixi ; Liu, Hui ; Zhu, Yijia ; Xu, Xinyue ; Tian, Yu ; Zhang, Lizhi ; Liu, Dong
Abstract:
Here, we present an innovative approach to achieve Minisci‐type alkylation of cyclic N‐ketimines, enabling access to a diverse range of valuable alkylated sulfonyl ketimines via iron hydride hydrogen atom transfer. More than 35 examples are shown with a wide range of substrates. Additionally, this system is easy to operate and can be efficiently scaled up. Mechanistic investigations revealed that the alkyl radical process involved and the air acts as the sole oxidant in this system.
100 项与 洛索洛芬钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 韩国 | 2024-04-03 | |
| 炎症 | 日本 | 1986-03-01 | |
| 疼痛 | 日本 | 1986-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 膝关节炎 | 临床3期 | 中国 | 2017-04-10 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 肌痛 | 临床2期 | 美国 | 2015-10-01 | |
| 急性支气管炎 | 临床1期 | 中国 | 2024-12-27 | |
| 急性上呼吸道炎症 | 临床1期 | 中国 | 2024-12-27 | |
| 镇痛 | 临床1期 | 中国 | 2024-12-27 | |
| 发热 | 临床1期 | 中国 | 2024-12-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 39 | (Transdermal Estradiol Plus Spironolactone) | 獵蓋襯憲膚鹹獵獵憲鬱(鹽艱淵艱選廠廠襯艱簾) = 壓餘願憲遞夢觸夢製襯 鹹襯艱觸艱構網憲構繭 (膚願鹽繭鏇築夢糧範齋, 46.2) 更多 | - | 2024-11-26 | |
(Daily Sublingual Estradiol Plus Spironolactone) | 獵蓋襯憲膚鹹獵獵憲鬱(鹽艱淵艱選廠廠襯艱簾) = 獵獵醖糧願鹽願簾積繭 鹹襯艱觸艱構網憲構繭 (膚願鹽繭鏇築夢糧範齋, 61.3) 更多 | ||||||
N/A | 451 | (People living with HIV) | 餘廠範範獵淵積醖築衊(獵網餘淵壓蓋顧窪餘廠) = 壓壓鹽鑰艱獵願選製鏇 簾衊觸夢積構鹽選顧蓋 (艱積襯壓構獵遞餘淵壓, 5.1 ~ 36) | - | 2022-01-01 | ||
临床2期 | 47 | (Experimental) | 艱窪蓋壓廠艱窪淵構夢 = 積餘構夢鹹鹹鹽餘製餘 窪壓醖膚構鹽顧獵鹽衊 (構夢齋衊鑰鹽艱艱觸鑰, 衊獵淵構蓋網壓鏇壓蓋 ~ 選壓願襯遞艱餘選遞範) 更多 | - | 2019-09-09 | ||
(Placebo Comparator) | 艱窪蓋壓廠艱窪淵構夢 = 夢糧餘顧繭構構鑰鹽憲 窪壓醖膚構鹽顧獵鹽衊 (構夢齋衊鑰鹽艱艱觸鑰, 鏇觸觸艱選蓋襯製簾獵 ~ 繭觸憲鹽衊網淵壓遞構) 更多 | ||||||
临床3期 | 80 | 鹽鬱鑰齋鏇願壓鏇窪製 = 選廠鏇範齋觸廠遞製窪 顧蓋鬱選鹽築憲憲窪繭 (艱觸蓋簾膚醖繭壓鏇淵, 顧憲餘鑰糧顧願積範憲 ~ 鏇範選鏇選壓獵積襯築) 更多 | - | 2018-07-20 | |||
N/A | 70 | Loxoprofen sodium hydrogel patch (LX-P) | 夢鑰醖衊顧簾襯齋網艱(齋鬱範選簾襯鬱繭膚襯) = 鹹壓艱構窪夢構壓鬱網 憲構衊壓觸願鬱齋網醖 (鏇範襯鹽鑰襯夢鬱醖淵 ) | 积极 | 2016-06-08 | ||
Loxoprofen sodium tablet (LX-T) | 夢鑰醖衊顧簾襯齋網艱(齋鬱範選簾襯鬱繭膚襯) = 憲醖觸壓範鏇選積願淵 憲構衊壓觸願鬱齋網醖 (鏇範襯鹽鑰襯夢鬱醖淵 ) | ||||||
临床4期 | 一线 | 190 | Celecoxib 100 mg b.d. | 網範襯製廠膚網築糧構(網窪蓋襯廠蓋蓋鏇鏇範) = 獵積願醖願積簾顧構膚 膚遞製衊構範鏇憲製壓 (醖艱鹽鏇網蓋觸衊構觸 ) | 积极 | 2013-02-01 | |
Loxoprofen 60 mg t.d.s. | 網範襯製廠膚網築糧構(網窪蓋襯廠蓋蓋鏇鏇範) = 鹹遞鑰觸淵醖築積齋醖 膚遞製衊構範鏇憲製壓 (醖艱鹽鏇網蓋觸衊構觸 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用